Top Markets
Coin of the day
Solasia Pharma K.K. Solasia Pharma K.K.

Solasia Pharma K.K.

4597
株式のランク #24757
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
株価
$0.20877985
時価総額
$57.00M
変化(1日)
-11.11%
変化(1年)
-20.59%
JP
取引 Solasia Pharma K.K. (4597)

カテゴリー

Solasia Pharma K.K.(4597)の株式分割履歴
Solasia Pharma K.K.株(シンボル:4597)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 21, 2026に行われました。
Aug 21, 2026より前に購入された4597株は、現在04597株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割